|drug1825||Lifestyle change promotion program Wiki||1.00|
|drug2042||Mindfullness based cognitive program Wiki||1.00|
|drug3459||Training video on anxiety, fear and loneliness in the COVID-19 environment. Wiki||1.00|
|D061218||Depressive Disorder, Treatment-Resistant NIH||1.00|
|D003866||Depressive Disorder NIH||0.20|
There is one clinical trial.
The main objective of the study will be to evaluate the effectiveness of an adjuvant lifestyle-based intervention for treatment-resistant patients with major depressive disorder. Patients will be allocated to one of these three groups: 1)Treatment prescribed by their mental health team plus written lifestyle change suggestions 2)Treatment prescribed by their mental health team plus written lifestyle change suggestions plus 8-week Mindfulness-based cognitive therapy (MBCT) program 3) Treatment prescribed by their mental health team plus written lifestyle change suggestions plus 8-week lifestyle change promotion program. We will collect patient data using the questionnaires administered at baseline, immediately after the intervention, and at six and 12-month follow-up. The primary outcome will be depression severity and secondary outcomes will include health-related quality of life.
Description: Beck Depression Inventory-II (BDI-II)Measure: Depression severity Time: 12 month
Description: Questionnaire (EQ-5D)Measure: Health-related quality of life Time: 12 month
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports